ସେଫୋକ୍ସିଟିନ

ସେଫୋକ୍ସିଟିନ
Clinical data
Trade names	Mefoxin, Renoxitin, others
Synonyms	Cephoxitin cefoxitin sodium
AHFS/Drugs.com	monograph
MedlinePlus	a682737
data	US DailyMed: Cefoxitin;
Pregnancy; category	AU: B1 ; US: N (Not classified yet) ; ;
Routes of; administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Metabolism	minimal
Elimination half-life	41-59 min
Excretion	85% urine
Identifiers
	IUPAC name (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy-; 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-; 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
ECHA InfoCard	100.047.841
Chemical and physical data
Formula	C16H17N3O7S2
Molar mass	୪୨୭.୪୫ g·mol−1
3D model (JSmol)	Interactive image;
Melting point	149 to 150 °C (300 to 302 °F) (dec.)
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)Cc3sccc3)COC(=O)N)C(=O)O;
	InChI InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1 ; Key:WZOZEZRFJCJXNZ-ZBFHGGJFSA-N ;
(verify)

ସେଫୋକ୍ସିଟିନ, ବେପାର ନାମ ମେଫୋକ୍ସିନ, ହେଉଛି ଏକ ଆଣ୍ଟିବାୟୋଟିକ୍, ଯାହା କିଡନୀ ସଂକ୍ରମଣ, ହାଡ଼ ସଂକ୍ରମଣ, ପେଲଭିସ ପ୍ରଦାହ ରୋଗ, ଉଦର ଭିତର ସଂକ୍ରମଣ, ନିମୋନିଆ ଏବଂ ସେପସିସ୍ ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୩] ^[୪] ଏହା ଏକ ଶିରାରେ ଇଞ୍ଜେକ୍ସନ ଆକାରରେ ଧୀରେ ଧୀରେ ଦିଆଯାଏ ।^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଆଲର୍ଜି ପ୍ରତିକ୍ରିୟା, ଇଞ୍ଜେକ୍ସନ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ଏବଂ ତରଳ ଝାଡ଼ା ହୋଇପାରେ । ^[୪] ଅନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ କ୍ଲୋଷ୍ଟ୍ରିଡିଏଡସ୍ ଡିଫାଇସିଲ୍ ସଂକ୍ରମଣ ଏବଂ ଅସ୍ଥି ମଜ୍ଜା ବିଫଳତା ହୋଇପାରେ । ^[୪] ^[୩] ଏହା ଗର୍ଭାବସ୍ଥାରେ କ୍ଷତିକାରକ ବୋଲି ଜଣା ନାହିଁ ଏବଂ ସ୍ତନ୍ୟପାନ କରାଇବା ସମୟରେ ଏହା ବ୍ୟବହାର କରାଯାଇପାରେ । ^[୩] ବୃକ୍)କ ଜନିତ ସମସ୍ୟାରେ କମ୍ ମାତ୍ରାର ଔସଧ ଆବଶ୍ୟକ ହୋଇପାରେ । ^[୪] ଏହା ଏକ ସେଫାମାଇସିନ୍; ଯଦିଓ ଦ୍ୱିତୀୟ ପିଢ଼ୀର ସେଫାଲୋସ୍ପୋରିନ୍ ସହିତ ଗୋଷ୍ଠୀଭୁକ୍ତ ହୁଏ | ^[୫] ^[୪]

୧୯୭୨ ମସିହାରେ ସେଫୋକ୍ସିଟିନ୍ ଆବିଷ୍କୃତ ହୋଇଥିଲା ଏବଂ ୧୯୭୮ରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୪] ^[୫] ଏହା ଏକ ସାଧାରଣ ଔଷଧ ଭାବରେ ଉପଲବ୍ଧ। ^[୬] ^[୭] ୨୦୨୧ରେ ଯୁକ୍ତରାଜ୍ୟରେ ୧୦ ମାତ୍ରାର ୨ ଗ୍ରାମ ଔଷଧର ମୂଲ୍ୟ £ ୩୦୦ରୁ କମ୍ ଥିଲା । ^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ପ୍ରାୟ ୧୧୦ଡଲାର ଅଟେ। ^[୮]

ଆଧାର

↑ "Cefoxitin International". Drugs.com. 2 November 2020. Archived from the original on 1 March 2016. Retrieved 8 November 2020.
↑ "Cefoxitin- cefoxitin sodium powder, for solution". DailyMed. 10 June 2020. Archived from the original on 18 January 2021. Retrieved 8 November 2020.
↑ ^୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "5. Infection". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 560. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)
↑ ^୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "CefOXitin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 30 December 2021.
↑ ^୫.୦ ^୫.୧ Levy, Stuart B. (2013-11-11). The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle (in ଇଂରାଜୀ). Springer. ISBN 9781489960429. Archived from the original on 2021-11-01. Retrieved 2021-07-06.
↑ "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Archived from the original on 2021-11-01. Retrieved 2017-05-04.
↑ "Supplement Approval" (PDF). Food and Drug Administration. Department of Health and Human Services. Archived from the original (PDF) on 2021-04-05. Retrieved 2021-07-06.
↑ "Cefoxitin Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 April 2021. Retrieved 30 December 2021.

[1] "Cefoxitin International". Drugs.com. 2 November 2020. Archived from the original on 1 March 2016. Retrieved 8 November 2020.

[Cefoxitin_FDA_label-2] "Cefoxitin- cefoxitin sodium powder, for solution". DailyMed. 10 June 2020. Archived from the original on 18 January 2021. Retrieved 8 November 2020.

[BNF82-3] ୩.୦ ^୩.୧ ^୩.୨ ^୩.୩ ^୩.୪ "5. Infection". British National Formulary (BNF) (82 ed.). London: BMJ Group and the Pharmaceutical Press. September 2021 – March 2022. p. 560. ISBN 978-0-85711-413-6.{{cite book}}: CS1 maint: date format (link)

[AHFS2021-4] ୪.୦ ^୪.୧ ^୪.୨ ^୪.୩ ^୪.୪ ^୪.୫ "CefOXitin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 19 January 2021. Retrieved 30 December 2021.

[Ant2013-5] ୫.୦ ^୫.୧ Levy, Stuart B. (2013-11-11). The Antibiotic Paradox: How Miracle Drugs Are Destroying the Miracle (in ଇଂରାଜୀ). Springer. ISBN 9781489960429. Archived from the original on 2021-11-01. Retrieved 2021-07-06.

[6] "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". www.accessdata.fda.gov. Archived from the original on 2021-11-01. Retrieved 2017-05-04.

[7] "Supplement Approval" (PDF). Food and Drug Administration. Department of Health and Human Services. Archived from the original (PDF) on 2021-04-05. Retrieved 2021-07-06.

[8] "Cefoxitin Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 15 April 2021. Retrieved 30 December 2021.

[୩]

[୪]

[୧]

[୨]

[୫]

[୬]

[୭]

[୮]

Clinical data

Trade names	Mefoxin, Renoxitin, others^[୧]
Synonyms	Cephoxitin cefoxitin sodium
AHFS/Drugs.com	monograph
MedlinePlus	a682737
data	US DailyMed: Cefoxitin
Pregnancy category	AU: B1 US: N (Not classified yet)
Routes of administration	Intravenous
Legal status
Legal status	AU: S4 (Prescription only) UK: POM (Prescription only) US: ℞-only ^[୨]
Pharmacokinetic data
Metabolism	minimal
Elimination half-life	41-59 min
Excretion	85% urine
Identifiers
IUPAC name (6R,7S)-3-(carbamoyloxymethyl)-7-methoxy- 8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
ECHA InfoCard	100.047.841
Chemical and physical data
Formula	C₁₆H₁₇N₃O₇S₂
Molar mass	୪୨୭.୪୫ g·mol⁻¹
3D model (JSmol)	Interactive image
Melting point	149 to 150 °C (300 to 302 °F) (dec.)
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)Cc3sccc3)COC(=O)N)C(=O)O
InChI InChI=1S/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1^Y Key:WZOZEZRFJCJXNZ-ZBFHGGJFSA-N^Y
(verify)